Showing results (121-130 of 129) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 129 results.
Journal of Pharmaceutical Health Care and Sciences|January 29, 2016
Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug eventsMitsuhiro Nakamura, Ryogo Umetsu, Junko Abe, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|February 10, 2011
Edaravone-loaded liposomes for retinal protection against oxidative stress-induced retinal damageKohei Hironaka, Yuta Inokuchi, Takuya Fujisawa, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|June 19, 2012
Transglycosylated rutin-specific non-surface-active nanostructure affects absorption enhancement of flurbiprofenYuichi Tozuka, Kenjirou Higashi, Takeshi Morita, et al.
Molecular Therapy. Nucleic Acids|April 26, 2016
Topical Use of Angiopoietin-like Protein 2 RNAi-loaded Lipid Nanoparticles Suppresses Corneal NeovascularizationYukako Taketani, Tomohiko Usui, Tetsuya Toyono, et al.
Medical Oncology (Northwood, London, England)|July 16, 2016
Preparation and clinical evaluation of a novel lozenge containing polaprezinc, a zinc-L-carnosine, for prevention of oral mucositis in patients with hematological cancer who received high-dose chemotherapyHiroko Hayashi, Ryo Kobayashi, Akio Suzuki, et al.
Cureus|October 3, 2025
Evaluation of Intraocular Anti-vascular Endothelial Growth Factor (VEGF) Drug-Associated Adverse Events Using Spontaneous Reporting DatabasesMugita Sato, Koichi Kageyama, Seiichiro Ito, et al.
Plos One|September 28, 2017
Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting systemAkiho Fukuda, Kohei Tahara, Yuuki Hane, et al.
SAGE Open Medicine|March 20, 2019
Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting SystemMisa Naganuma, Kohei Tahara, Shiori Hasegawa, et al.
Chemical & Pharmaceutical Bulletin|December 10, 2020
Approach to Establishment of Control Strategy for Oral Solid Dosage Forms Using Continuous ManufacturingHayato Ishimoto, Manabu Kano, Hirokazu Sugiyama, et al.
Pageof 13